{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:31:20Z","timestamp":1789594280238,"version":"build-2803163510"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01298-8","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:48:50Z","timestamp":1746064130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-3752","authenticated-orcid":false,"given":"Maya S.","family":"Safarova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1254-9344","authenticated-orcid":false,"given":"Spencer","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sadaniantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Kovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Garshick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Gianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"issue":"25","key":"1298_CR1","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"9841","key":"1298_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"24","key":"1298_CR3","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1298_CR4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avina-Zubieta","year":"2008","unstructured":"Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690\u20137.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1298_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","volume":"19","author":"BN Weber","year":"2023","unstructured":"Weber BN, Giles JT, Liao KP. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat Rev Rheumatol. 2023;19(7):417\u201328.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1298_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","volume":"16","author":"AG Semb","year":"2020","unstructured":"Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020;16(7):361\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1298_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","volume":"77","author":"CS Crowson","year":"2018","unstructured":"Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel P, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1298_CR8","doi-asserted-by":"publisher","first-page":"e001588","DOI":"10.1161\/JAHA.114.001588","volume":"4","author":"KP Liao","year":"2015","unstructured":"Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4(2):e001588.","journal-title":"J Am Heart Assoc."},{"issue":"11","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","volume":"76","author":"J Robertson","year":"2017","unstructured":"Robertson J, Porter D, Sattar N, Packard CJ, Caslake M, McInnes I, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017;76(11):1949\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1298_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","volume":"110","author":"CS Crowson","year":"2012","unstructured":"Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110(3):420\u20134.","journal-title":"Am J Cardiol"},{"issue":"12","key":"1298_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11883-017-0685-7","volume":"19","author":"M Garshick","year":"2017","unstructured":"Garshick M, Underberg JA. The use of primary prevention statin therapy in those predisposed to atherosclerosis. Curr Atheroscler Rep. 2017;19(12):48.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"1298_CR12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376\u2013414.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1298_CR13","doi-asserted-by":"publisher","first-page":"e000771","DOI":"10.1136\/rmdopen-2018-000771","volume":"4","author":"L Ljung","year":"2018","unstructured":"Ljung L, Ueda P, Liao KP, Greenberg JD, Etzel CJ, Solomon DH, et al. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation. RMD Open. 2018;4(2):e000771.","journal-title":"RMD Open"},{"issue":"2","key":"1298_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3899\/jrheum.171008","volume":"46","author":"B Wahlin","year":"2019","unstructured":"Wahlin B, Innala L, Magnusson S, Moller B, Smedby T, Rantapaa-Dahlqvist S, et al. Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis is not superior to the ACC\/AHA risk calculator. J Rheumatol. 2019;46(2):130\u20137.","journal-title":"J Rheumatol"},{"issue":"37","key":"1298_CR15","doi-asserted-by":"publisher","first-page":"e35088","DOI":"10.1097\/MD.0000000000035088","volume":"102","author":"C Ren","year":"2023","unstructured":"Ren C, Li M. The efficacy of statins in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(37):e35088.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"1298_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/annrheumdis-2015-207714","volume":"75","author":"SR Schoenfeld","year":"2016","unstructured":"Schoenfeld SR, Lu L, Rai SK, Seeger JD, Zhang Y, Choi HK. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis. 2016;75(7):1315\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1298_CR17","first-page":"296","volume":"27","author":"A Chhibber","year":"2021","unstructured":"Chhibber A, Hansen S, Biskupiak J. Statin use and mortality in rheumatoid arthritis: an incident user cohort study. J Manag Care Spec Pharm. 2021;27(3):296\u2013305.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"1298_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/art.40892","volume":"71","author":"GD Kitas","year":"2019","unstructured":"Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM, et al. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1437\u201349.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1298_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694\u2013702.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1298_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"key":"1298_CR21","unstructured":"Giles JT, Charles-Schoeman C, Buch M, Dougados M, Zoltan S, Mikuls T, et al. Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis. ACR Converg. 2024. 2024."},{"issue":"1","key":"1298_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71\u201380.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1298_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","volume":"43","author":"SR Schoenfeld","year":"2013","unstructured":"Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77\u201395.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1298_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3899\/jrheum.150437","volume":"43","author":"L Durcan","year":"2016","unstructured":"Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, Petri M. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol. 2016;43(4):745\u201350.","journal-title":"J Rheumatol"},{"issue":"1","key":"1298_CR25","doi-asserted-by":"publisher","first-page":"e000448","DOI":"10.1136\/lupus-2020-000448","volume":"8","author":"J Sivakumaran","year":"2021","unstructured":"Sivakumaran J, Harvey P, Omar A, Tayer-Shifman O, Urowitz MB, Gladman DD, et al. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med. 2021;8(1):e000448.","journal-title":"Lupus Sci Med."},{"key":"1298_CR26","doi-asserted-by":"publisher","first-page":"152468","DOI":"10.1016\/j.semarthrit.2024.152468","volume":"67","author":"MY Choi","year":"2024","unstructured":"Choi MY, Guan H, Yoshida K, Paudel M, Kargere BA, Li D, et al. Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2024;67:152468.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1298_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/ard.2010.133827","volume":"70","author":"SI van Leuven","year":"2011","unstructured":"van Leuven SI, Mendez-Fernandez YV, Stroes ES, Tak PP, Major AS. Statin therapy in lupus-mediated atherogenesis: two birds with one stone? Ann Rheum Dis. 2011;70(2):245\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1298_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.14423\/SMJ.0000000000000561","volume":"109","author":"RT Artola","year":"2016","unstructured":"Artola RT, Mihos CG, Santana O. Effects of statin therapy in patients with systemic lupus erythematosus. South Med J. 2016;109(11):705\u201311.","journal-title":"South Med J"},{"issue":"1","key":"1298_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","volume":"243","author":"HH Yu","year":"2015","unstructured":"Yu HH, Chen PC, Yang YH, Wang LC, Lee JH, Lin YT, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. Atherosclerosis. 2015;243(1):11\u20138.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1298_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kead184","volume":"63","author":"N Papazoglou","year":"2024","unstructured":"Papazoglou N, Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford). 2024;63(1):50\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1298_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/art.30645","volume":"64","author":"LE Schanberg","year":"2012","unstructured":"Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285\u201396.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1298_CR32","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2665-9913(24)00090-0","volume":"6","author":"E Bolla","year":"2024","unstructured":"Bolla E, Semb AG, Kerola AM, Ikdahl E, Petri M, Pons-Estel GJ, et al. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries. Lancet Rheumatol. 2024;6(7):e447\u201359.","journal-title":"Lancet Rheumatol"},{"issue":"13","key":"1298_CR33","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021;77(13):1670\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1298_CR34","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/ATVBAHA.119.314008","volume":"40","author":"MS Garshick","year":"2020","unstructured":"Garshick MS, Tawil M, Barrett TJ, Salud-Gnilo CM, Eppler M, Lee A, et al. Activated platelets induce endothelial cell inflammatory response in psoriasis via COX-1. Arterioscler Thromb Vasc Biol. 2020;40(5):1340\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1298_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacbts.2018.10.008","volume":"4","author":"HL Teague","year":"2019","unstructured":"Teague HL, Varghese NJ, Tsoi LC, Dey AK, Garshick MS, Silverman JI, et al. Neutrophil subsets, platelets, and vascular disease in psoriasis. JACC Basic Transl Sci. 2019;4(1):1\u201314.","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"1298_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/ATVBAHA.118.312246","volume":"39","author":"MS Garshick","year":"2019","unstructured":"Garshick MS, Barrett TJ, Wechter T, Azarchi S, Scher JU, Neimann A, et al. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler Thromb Vasc Biol. 2019;39(4):787\u201398.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1298_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2475530320950268","volume":"5","author":"AV Sorokin","year":"2020","unstructured":"Sorokin AV, Remaley AT, Mehta NN. Oxidized lipids and lipoprotein dysfunction in psoriasis. J Psoriasis Psoriatic Arthritis. 2020;5(4):139\u201346.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"4","key":"1298_CR38","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1298_CR39","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","volume":"148","author":"JJ Wu","year":"2012","unstructured":"Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244\u201350.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1298_CR40","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jid.2021.07.190","volume":"142","author":"MS Garshick","year":"2022","unstructured":"Garshick MS, Drenkova K, Barrett TJ, Schlamp F, Fisher EA, Katz S, et al. A randomized open-label clinical trial of lipid-lowering therapy in psoriasis to reduce vascular endothelial inflammation. J Invest Dermatol. 2022;142(6):1749-52e4.","journal-title":"J Invest Dermatol."},{"issue":"9","key":"1298_CR41","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1111\/jdv.19191","volume":"37","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero A, Boehncke WH, De Sutter J, Zamorano JL, Lambert J, Puig L. Statins and psoriasis: position statement by the psoriasis task force of the European Academy of dermatology and venerology. J Eur Acad Dermatol Venereol. 2023;37(9):1697\u2013705.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1298_CR42","first-page":"60","volume":"3","author":"E Cozzani","year":"2009","unstructured":"Cozzani E, Scaparro M, Parodi A. A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep. 2009;3(4):60\u20131.","journal-title":"J Dermatol Case Rep"},{"issue":"1","key":"1298_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2019.90343","volume":"16","author":"M Socha","year":"2020","unstructured":"Socha M, Pietrzak A, Grywalska E, Pietrzak D, Matosiuk D, Kicinski P, et al. The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials. Arch Med Sci. 2020;16(1):1\u20137.","journal-title":"Arch Med Sci"},{"issue":"4","key":"1298_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/24755303231201336","volume":"8","author":"P Kingston","year":"2023","unstructured":"Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023;8(4):156\u201365.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"21","key":"1298_CR45","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395.","journal-title":"Circulation"},{"issue":"8","key":"1298_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914\u201356.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"1298_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","volume":"13","author":"BA Warden","year":"2019","unstructured":"Warden BA, Duell PB. Management of dyslipidemia in adult solid organ transplant recipients. J Clin Lipidol. 2019;13(2):231\u201345.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1298_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jacc.2023.04.050","volume":"82","author":"DK Kalra","year":"2023","unstructured":"Kalra DK, Vorla M, Michos ED, Agarwala A, Virani S, Duell PB, et al. Dyslipidemia in human immunodeficiency virus disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82(2):171\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1298_CR49","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living With HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"issue":"5","key":"1298_CR50","doi-asserted-by":"publisher","first-page":"e004987","DOI":"10.1161\/JAHA.116.004987","volume":"6","author":"JV Baker","year":"2017","unstructured":"Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc. 2017;6(5):e004987.","journal-title":"J Am Heart Assoc."},{"issue":"21","key":"1298_CR51","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.117.028975","volume":"137","author":"VA Triant","year":"2018","unstructured":"Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation. 2018;137(21):2203\u201314.","journal-title":"Circulation"},{"issue":"3","key":"1298_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/QAI.0b013e31817bbbf0","volume":"48","author":"SA Riddler","year":"2008","unstructured":"Riddler SA, Li X, Otvos J, Post W, Palella F, Kingsley L, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2008;48(3):281\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1298_CR53","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1194\/jlr.M088153","volume":"59","author":"O Tort","year":"2018","unstructured":"Tort O, Escrib\u00e0 T, Ega\u00f1a-Gorro\u00f1o L, de Lazzari E, Cofan M, Fernandez E, et al. Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed. J Lipid Res. 2018;59(11):2108\u201315.","journal-title":"J Lipid Res"},{"issue":"4","key":"1298_CR54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurjpc\/zwab201","volume":"29","author":"B Delabays","year":"2022","unstructured":"Delabays B, Cavassini M, Damas J, Beuret H, Calmy A, Hasse B, et al. Cardiovascular risk assessment in people living with HIV compared to the general population. Eur J Prev Cardiol. 2022;29(4):689\u201399.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1298_CR55","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2047487315579291","volume":"23","author":"N Friis-M\u00f8ller","year":"2016","unstructured":"Friis-M\u00f8ller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23(2):214\u201323.","journal-title":"Eur J Prev Cardiol"},{"issue":"6 Suppl","key":"1298_CR56","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National lipid association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol. 2015;9(6 Suppl):S1-122.e1.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"1298_CR57","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3018(17)30075-9","volume":"4","author":"JA Aberg","year":"2017","unstructured":"Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4(7):e284\u201394.","journal-title":"Lancet HIV"},{"issue":"14","key":"1298_CR58","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1097\/QAD.0000000000001167","volume":"30","author":"CT Longenecker","year":"2016","unstructured":"Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30(14):2195\u2013203.","journal-title":"AIDS"},{"issue":"2","key":"1298_CR59","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","volume":"2","author":"J Lo","year":"2015","unstructured":"Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52-63.","journal-title":"Lancet HIV"},{"issue":"8","key":"1298_CR60","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/cid\/ciu523","volume":"59","author":"CT Longenecker","year":"2014","unstructured":"Longenecker CT, Hileman CO, Funderburg NT, Mccomsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148\u201356.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"1298_CR61","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/aid.2020.0273","volume":"37","author":"AA Ashuro","year":"2021","unstructured":"Ashuro AA, Fan YG, Fu YS, Di DS, Sam NB, Pan HF, et al. The effect of rosuvastatin on plasma\/serum levels of high-sensitivity c-reactive protein, interleukin-6, and d-dimer in people living with human immunodeficiency virus: a systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2021;37(11):821\u201333.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"1298_CR62","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"issue":"14","key":"1298_CR63","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2022;80(14):1366\u2013418.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1298_CR64","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the american heart association\/american college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9\u2013119.","journal-title":"Circulation"},{"key":"1298_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-8-7","volume":"11","author":"D Lee","year":"2022","unstructured":"Lee D. HIV: how to manage dyslipidaemia in HIV. Drugs Context. 2022;11:1\u20139.","journal-title":"Drugs Context"},{"key":"1298_CR66","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Accessed September 12, 2024 [Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/drug-interactions-overview]."},{"key":"1298_CR67","doi-asserted-by":"crossref","unstructured":"Lee D. HIV: how to manage dyslipidaemia in HIV. Drugs Context. 2022;11.","DOI":"10.7573\/dic.2021-8-7"},{"issue":"11","key":"1298_CR68","doi-asserted-by":"publisher","first-page":"e13032","DOI":"10.1111\/ijcp.13032","volume":"71","author":"M Kohli","year":"2017","unstructured":"Kohli M, Patel K, MacMahon Z, Ramachandran R, Crook MA, Reynolds TM, et al. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017;71(11):e13032.","journal-title":"Int J Clin Pract."},{"issue":"6","key":"1298_CR69","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"6","key":"1298_CR70","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168\u201385.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1298_CR71","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u201354.","journal-title":"Hepatology"},{"issue":"9756","key":"1298_CR72","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916\u201322.","journal-title":"Lancet"},{"issue":"8","key":"1298_CR73","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1210\/jc.2017-00867","volume":"102","author":"F Bril","year":"2017","unstructured":"Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, et al. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. J Clin Endocrinol Metab. 2017;102(8):2950\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1298_CR74","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287\u201392.","journal-title":"Gastroenterology"},{"issue":"6","key":"1298_CR75","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","volume":"78","author":"SR Sharpton","year":"2023","unstructured":"Sharpton SR, Loomba R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology. 2023;78(6):1896\u2013906.","journal-title":"Hepatology"},{"issue":"6","key":"1298_CR76","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","volume":"61","author":"P Blais","year":"2016","unstructured":"Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61(6):1714\u201320.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1298_CR77","doi-asserted-by":"publisher","first-page":"e2320222","DOI":"10.1001\/jamanetworkopen.2023.20222","volume":"6","author":"MS Vell","year":"2023","unstructured":"Vell MS, Loomba R, Krishnan A, Wangensteen KJ, Trebicka J, Creasy KT, et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open. 2023;6(6):e2320222.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1298_CR78","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/liv.15656","volume":"43","author":"SY Wu","year":"2023","unstructured":"Wu SY, Chen WM, Chiang MF, Lo HC, Wu MS, Lee MC, et al. Protective effects of statins on the incidence of NAFLD-related decompensated cirrhosis in T2DM. Liver Int. 2023;43(10):2232\u201344.","journal-title":"Liver Int"},{"issue":"3","key":"1298_CR79","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s44197-024-00205-9","volume":"14","author":"J Yoo","year":"2024","unstructured":"Yoo J, Jeon J, Baik M, Kim J. Effect of statins for primary prevention of cardiovascular disease according to the fatty liver index. J Epidemiol Glob Health. 2024;14(3):710\u20139.","journal-title":"J Epidemiol Glob Health"},{"issue":"4","key":"1298_CR80","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cgh.2023.04.017","volume":"22","author":"R Sharma","year":"2024","unstructured":"Sharma R, Simon TG, Hagstr\u00f6m H, Lochhead P, Roelstraete B, S\u00f6derling J, et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease. Clin Gastroenterol Hepatol. 2024;22(4):749-59.e19.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1298_CR81","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.eprac.2024.08.002","volume":"30","author":"AD Schreiner","year":"2024","unstructured":"Schreiner AD, Zhang J, Moran WP, Koch DG, Marsden J, Bays C, et al. Objective measures of cardiometabolic risk and advanced fibrosis risk progression in primary care patients with metabolic dysfunction-associated steatotic liver disease. Endocr Pract. 2024;30(11):1015\u201322.","journal-title":"Endocr Pract"},{"issue":"1","key":"1298_CR82","doi-asserted-by":"publisher","first-page":"e001404","DOI":"10.1136\/bmjgast-2024-001404","volume":"11","author":"AD Schreiner","year":"2024","unstructured":"Schreiner AD, Zhang J, Petz CA, Moran WP, Koch DG, Marsden J, et al. Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD. BMJ Open Gastroenterol. 2024;11(1):e001404.","journal-title":"BMJ Open Gastroenterol."},{"issue":"11","key":"1298_CR83","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","volume":"73","author":"XD Zhou","year":"2024","unstructured":"Zhou XD, Kim SU, Yip TC, Petta S, Nakajima A, Tsochatzis E, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883\u201392.","journal-title":"Gut"},{"issue":"5","key":"1298_CR84","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/jgh.16495","volume":"39","author":"W Amjad","year":"2024","unstructured":"Amjad W, Jiang Z, Lai M. Statin use in cirrhosis and its association with incidence of portal vein thrombosis. J Gastroenterol Hepatol. 2024;39(5):955\u201363.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1298_CR85","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/10815589241248076","volume":"72","author":"R Shah","year":"2024","unstructured":"Shah R, Kong A, De Melo S, Boktor M, Henriquez R, Mandalia A, et al. Association of statins with nonalcoholic fatty liver disease in patients with diabetes. J Investig Med. 2024;72(6):497\u2013510.","journal-title":"J Investig Med"},{"issue":"4","key":"1298_CR86","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1016\/j.jacl.2024.03.003","volume":"18","author":"A Ho","year":"2024","unstructured":"Ho A, Kiener T, Nguyen QN, Le QA. Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). J Clin Lipidol. 2024;18(4):e501\u20138.","journal-title":"J Clin Lipidol"},{"issue":"26","key":"1298_CR87","doi-asserted-by":"publisher","first-page":"e33981","DOI":"10.1097\/MD.0000000000033981","volume":"102","author":"H Zhou","year":"2023","unstructured":"Zhou H, Toshiyoshi M, Zhao W, Zhao Y. Statins on nonalcoholic fatty liver disease: a systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1298_CR88","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/MJT.0000000000001499","volume":"30","author":"W Dai","year":"2023","unstructured":"Dai W, Xu B, Li P, Weng J. Statins for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis. Am J Ther. 2023;30(1):e17\u201325.","journal-title":"Am J Ther"},{"issue":"5","key":"1298_CR89","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","volume":"136","author":"HB El-Serag","year":"2009","unstructured":"El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136(5):1601\u20138.","journal-title":"Gastroenterology"},{"issue":"7","key":"1298_CR90","first-page":"1077","volume":"12","author":"B Feng","year":"2024","unstructured":"Feng B, Li F, Lan Y, Wang X, Chen S, Yang C, et al. Statin use and development and progression of non-alcohol fatty liver disease based on ultrasonography: a cohort study. J Clin Endocrinol Metab. 2024;12(7):1077.","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"1298_CR91","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol. 2015;26(10):2504\u201311.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1298_CR92","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157\u201372.","journal-title":"Circulation"},{"issue":"6","key":"1298_CR93","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and validation of the American Heart Association\u2019s prevent equations. Circulation. 2024;149(6):430\u201349.","journal-title":"Circulation"},{"issue":"24","key":"1298_CR94","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation. 2023;148(24):1982\u20132004.","journal-title":"Circulation"},{"issue":"6","key":"1298_CR95","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","volume":"67","author":"X Su","year":"2016","unstructured":"Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, et al. Effect of statins on kidney disease outcomes: A systematic review and meta-analysis. Am J Kidney Dis. 2016;67(6):881\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1298_CR96","doi-asserted-by":"publisher","first-page":"16276","DOI":"10.1038\/s41598-018-34632-z","volume":"8","author":"PJ Hu","year":"2018","unstructured":"Hu PJ, Wu MY, Lin TC, Chen TT, Wu YC, Su SL, et al. Effect of statins on renal function in chronic kidney disease patients. Sci Rep. 2018;8(1):16276.","journal-title":"Sci Rep"},{"issue":"4S","key":"1298_CR97","first-page":"S117","volume":"105","author":"Group KDIGOKCW","year":"2024","unstructured":"Group KDIGOKCW. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int."},{"issue":"6","key":"1298_CR98","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, Members KDIGOLGDWG. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303\u20139.","journal-title":"Kidney Int."},{"issue":"1","key":"1298_CR99","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"8","key":"1298_CR100","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129\u201350.","journal-title":"Can J Cardiol"},{"issue":"3","key":"1298_CR101","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348.","journal-title":"N Engl J Med"},{"issue":"14","key":"1298_CR102","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"issue":"9784","key":"1298_CR103","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"1","key":"1298_CR104","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","volume":"61","author":"SL Seliger","year":"2002","unstructured":"Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61(1):297\u2013304.","journal-title":"Kidney Int"},{"issue":"1","key":"1298_CR105","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ajkd.2004.09.025","volume":"45","author":"NA Mason","year":"2005","unstructured":"Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45(1):119\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1298_CR106","doi-asserted-by":"publisher","first-page":"e014840","DOI":"10.1161\/JAHA.119.014840","volume":"9","author":"J Jung","year":"2020","unstructured":"Jung J, Bae GH, Kang M, Kim SW, Lee DH. Statins and all-cause mortality in patients undergoing hemodialysis. J Am Heart Assoc. 2020;9(5):e014840.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1298_CR107","doi-asserted-by":"publisher","first-page":"e2229706","DOI":"10.1001\/jamanetworkopen.2022.29706","volume":"5","author":"HY Lo","year":"2022","unstructured":"Lo HY, Lin YS, Lin DS, Lee JK, Chen WJ. Association of statin therapy with major adverse cardiovascular and limb outcomes in patients with end-stage kidney disease and peripheral artery disease receiving maintenance dialysis. JAMA Netw Open. 2022;5(9):e2229706.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1298_CR108","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/0886022X.2021.1915799","volume":"43","author":"L Zhao","year":"2021","unstructured":"Zhao L, Li S, Gao Y. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2021;43(1):718\u201328.","journal-title":"Ren Fail"},{"issue":"5","key":"1298_CR109","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacl.2021.09.046","volume":"15","author":"PWF Wilson","year":"2021","unstructured":"Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le NA, Davidson MH, et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021;15(5):629\u201348.","journal-title":"J Clin Lipidol"},{"issue":"36","key":"1298_CR110","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.2174\/138161206779026308","volume":"12","author":"IF Gazi","year":"2006","unstructured":"Gazi IF, Liberopoulos EN, Athyros VG, Elisaf M, Mikhailidis DP. Statins and solid organ transplantation. Curr Pharm Des. 2006;12(36):4771\u201383.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1298_CR111","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1161\/01.ATV.0000067060.31369.F9","volume":"23","author":"M Weis","year":"2003","unstructured":"Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol. 2003;23(4):567\u201375.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"1298_CR112","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/tri.12149","volume":"26","author":"L Mart\u00ednez-Dolz","year":"2013","unstructured":"Mart\u00ednez-Dolz L, S\u00e1nchez-L\u00e1zaro IJ, Almenar-Bonet L, Portol\u00e9s M, Rivera M, Salvador A, et al. Metabolic syndrome in heart transplantation: impact on survival and renal function. Transpl Int. 2013;26(9):910\u20138.","journal-title":"Transpl Int"},{"issue":"1","key":"1298_CR113","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","volume":"6","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Prasad GV. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant. 2016;6(1):125\u201334.","journal-title":"World J Transplant"},{"issue":"5","key":"1298_CR114","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/ehf2.12784","volume":"7","author":"JR Golbus","year":"2020","unstructured":"Golbus JR, Adie S, Yosef M, Murthy VL, Aaronson KD, Konerman MC. Statin intensity and risk for cardiovascular events after heart transplantation. ESC Heart Fail. 2020;7(5):2074\u201381.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"1298_CR115","doi-asserted-by":"publisher","first-page":"e003265","DOI":"10.1161\/CIRCHEARTFAILURE.116.003265","volume":"9","author":"A Vallakati","year":"2016","unstructured":"Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of statin use after heart transplantation: a meta-analysis. Circ Heart Fail. 2016;9(10):e003265.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1298_CR116","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jacl.2024.10.005","volume":"19","author":"AS Birs","year":"2024","unstructured":"Birs AS, Kao AS, Silver E, Adler ED, Taub PR, Wilkinson MJ. Burden of atherogenic lipids and association with cardiac allograft vasculopathy in heart transplant recipients. J Clin Lipidol. 2024;19(1):134.","journal-title":"J Clin Lipidol."},{"issue":"1","key":"1298_CR117","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12944-024-02276-w","volume":"23","author":"I Bellos","year":"2024","unstructured":"Bellos I, Lagiou P, Benetou V, Marinaki S. Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis. Lipids Health Dis. 2024;23(1):293.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"1298_CR118","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.transproceed.2011.12.010","volume":"44","author":"H Harada","year":"2012","unstructured":"Harada H, Nakamura M, Hotta K, Iwami D, Seki T, Togashi M, et al. Percentages of water, muscle, and bone decrease and lipid increases in early period after successful kidney transplantation: a body composition analysis. Transplant Proc. 2012;44(3):672\u20135.","journal-title":"Transplant Proc"},{"issue":"12","key":"1298_CR119","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.3748\/wjg.v22.i12.3315","volume":"22","author":"A H\u00fcsing","year":"2016","unstructured":"H\u00fcsing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. World J Gastroenterol. 2016;22(12):3315\u201324.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1298_CR120","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.healun.2005.02.009","volume":"24","author":"JA Kobashigawa","year":"2005","unstructured":"Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005;24(11):1736\u201340.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"1298_CR121","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","volume":"107","author":"K Wenke","year":"2003","unstructured":"Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107(1):93\u20137.","journal-title":"Circulation"},{"issue":"5","key":"1298_CR122","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00059-005-2685-6","volume":"30","author":"K Wenke","year":"2005","unstructured":"Wenke K, Meiser B, Thiery J, Reichart B. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz. 2005;30(5):431\u20132.","journal-title":"Herz"},{"issue":"8","key":"1298_CR123","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.119.039932","volume":"140","author":"AI Nyk\u00e4nen","year":"2019","unstructured":"Nyk\u00e4nen AI, Holmstr\u00f6m EJ, Tuuminen R, Krebs R, Dhaygude K, Kankainen M, et al. Donor simvastatin treatment in heart transplantation. Circulation. 2019;140(8):627\u201340.","journal-title":"Circulation"},{"issue":"1","key":"1298_CR124","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0002-9149(03)00456-9","volume":"92","author":"VY See","year":"2003","unstructured":"See VY, DeNofrio D, Goldberg L, Chang G, Sasseen B, Kolansky DM, et al. Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol. 2003;92(1):11\u20135.","journal-title":"Am J Cardiol"},{"issue":"9","key":"1298_CR125","doi-asserted-by":"publisher","first-page":"e086352","DOI":"10.1136\/bmjopen-2024-086352","volume":"14","author":"A Evans","year":"2024","unstructured":"Evans A, Mawson P, Thomas H, Keen K, Watson CJ, McAuley DF, et al. SIGNET: protocol for a multicentre, single-blind prospective, group sequential, randomised controlled trial to evaluate the benefits of a single dose of simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients. BMJ Open. 2024;14(9):e086352.","journal-title":"BMJ Open"},{"issue":"9374","key":"1298_CR126","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024\u201331.","journal-title":"Lancet"},{"issue":"12","key":"1298_CR127","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","volume":"5","author":"H Holdaas","year":"2005","unstructured":"Holdaas H, Fellstr\u00f6m B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929\u201336.","journal-title":"Am J Transplant"},{"issue":"8","key":"1298_CR128","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.transproceed.2019.04.087","volume":"51","author":"SD Hwang","year":"2019","unstructured":"Hwang SD, Lee JH, Jhee JH, Kim YJ, Park KM, Kim JK, et al. Effect of Fluvastatin on cardiovascular complications in kidney transplant patients: a systemic review and meta-analysis. Transplant Proc. 2019;51(8):2710\u20133.","journal-title":"Transplant Proc"},{"issue":"7","key":"1298_CR129","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/apt.17192","volume":"56","author":"C Becchetti","year":"2022","unstructured":"Becchetti C, Dirchwolf M, Schropp J, Magini G, M\u00fcllhaupt B, Immer F, et al. Use of statins after liver transplantation is associated with improved survival: results of a nationwide study. Aliment Pharmacol Ther. 2022;56(7):1194\u2013204.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1298_CR130","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1097\/TP.0000000000004220","volume":"106","author":"D Pagano","year":"2022","unstructured":"Pagano D, Bosch J, Tuzzolino F, Oliva E, Ekser B, Zito G, et al. Donor simvastatin treatment is safe and might improve outcomes after liver transplantation: a randomized clinical trial. Transplantation. 2022;106(12):2379\u201390.","journal-title":"Transplantation"},{"issue":"4","key":"1298_CR131","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1097\/TP.0000000000004501","volume":"107","author":"F \u00c5berg","year":"2023","unstructured":"\u00c5berg F, Nyk\u00e4nen AI, Helanter\u00e4 I, Lemstr\u00f6m K. Donor simvastatin treatment in liver transplantation: post hoc analysis of a randomized placebo-controlled trial with long-term follow-up. Transplantation. 2023;107(4):e122\u20133.","journal-title":"Transplantation"},{"issue":"4","key":"1298_CR132","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/TP.0b013e318225670d","volume":"92","author":"Y Li","year":"2011","unstructured":"Li Y, Gottlieb J, Ma D, Kuehn C, Strueber M, Welte T, et al. Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation\u2013a propensity score analysis with 23 years of follow-up. Transplantation. 2011;92(4):486\u201392.","journal-title":"Transplantation"},{"issue":"9","key":"1298_CR133","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.healun.2017.05.007","volume":"36","author":"J Raphael","year":"2017","unstructured":"Raphael J, Collins SR, Wang XQ, Scalzo DC, Singla P, Lau CL, et al. Perioperative statin use is associated with decreased incidence of primary graft dysfunction after lung transplantation. J Heart Lung Transplant. 2017;36(9):948\u201356.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"1298_CR134","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/hc0602.103393","volume":"105","author":"M Weis","year":"2002","unstructured":"Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739\u201345.","journal-title":"Circulation"},{"issue":"Suppl 7","key":"1298_CR135","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","volume":"4","author":"B Kasiske","year":"2004","unstructured":"Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4(Suppl 7):13\u201353.","journal-title":"Am J Transplant"},{"issue":"2","key":"1298_CR136","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1060028019871891","volume":"54","author":"DR Migliozzi","year":"2020","unstructured":"Migliozzi DR, Asal NJ. Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions. Ann Pharmacother. 2020;54(2):171\u20137.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"1298_CR137","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","volume":"5","author":"WP Lemahieu","year":"2005","unstructured":"Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005;5(9):2236\u201343.","journal-title":"Am J Transplant"},{"issue":"3","key":"1298_CR138","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","volume":"65","author":"MJ Sarnak","year":"2015","unstructured":"Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis. 2015;65(3):354\u201366.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1298_CR139","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/lt.23566","volume":"19","author":"MR Lucey","year":"2013","unstructured":"Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3\u201326.","journal-title":"Liver Transpl"},{"issue":"3","key":"1298_CR140","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jaccas.2019.09.026","volume":"2","author":"BA Warden","year":"2020","unstructured":"Warden BA, Kaufman T, Minnier J, Duell PB, Fazio S, Shapiro MD. Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients. JACC Case Rep. 2020;2(3):396\u20139.","journal-title":"JACC Case Rep"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01298-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:02:54Z","timestamp":1746108174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01298-8","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"6 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"54"}}